Pharsight

Amvuttra is owned by Alnylam Pharms Inc.

Amvuttra contains Vutrisiran.

Amvuttra has a total of 12 drug patents out of which 0 drug patents have expired.

Amvuttra was authorised for market use on 13 June, 2022.

Amvuttra is available in solution;subcutaneous dosage forms.

Amvuttra can be used as amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Drug patent challenges can be filed against Amvuttra from 2026-06-13.

The generics of Amvuttra are possible to be released after 28 July, 2036.

Application	Filing Date	Opposition Party	Legal Status
EP17209680A	2023-01-27	AWA Sweden AB	Granted and Under Opposition

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10131907	ALNYLAM PHARMS INC	Glycoconjugates of RNA interference agents	Aug, 2028 (5 years from now)
US10806791	ALNYLAM PHARMS INC	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec, 2028 (5 years from now)
US9370581	ALNYLAM PHARMS INC	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec, 2028 (5 years from now)
US8828956	ALNYLAM PHARMS INC	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec, 2028 (5 years from now)
US8106022	ALNYLAM PHARMS INC	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec, 2029 (6 years from now)
US10570391	ALNYLAM PHARMS INC	RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases	Nov, 2032 (9 years from now)
US9399775	ALNYLAM PHARMS INC	RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases	Nov, 2032 (9 years from now)
US10612024	ALNYLAM PHARMS INC	Modified double-stranded RNA agents	Aug, 2035 (12 years from now)
US11401517	ALNYLAM PHARMS INC	Modified double-stranded RNA agents	Aug, 2035 (12 years from now)
US10208307	ALNYLAM PHARMS INC	Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases	Jul, 2036 (13 years from now)
US11286486	ALNYLAM PHARMS INC	Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases	Jul, 2036 (13 years from now)
US10683501	ALNYLAM PHARMS INC	Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases	Jul, 2036 (13 years from now)